NEUROCRINE BIOSCIENCES INC— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$806M
↑+28.3% +$178Mvs FY2024 (Q4)
Gross Profit
$788M
↑+27.4% +$170Mvs FY2024 (Q4)
Operating Income
$211M
↑+48.5% +$69Mvs FY2024 (Q4)
Net Income
$154M
↑+49.1% +$51Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $806M | $628M |
| COGS | $18M | $9M |
| Gross Profit | $788M | $618M |
| R&D | $258M | $186M |
| SG&A | $302M | $288M |
| D&A | $6M | $3M |
| Other OpEx | $11M | $0 |
| Operating Income | $211M | $142M |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $211M | $142M |
| Tax | $57M | $39M |
| Net Income | $154M | $103M |
QuarterCharts · SEC EDGAR data · NBIX · Comparing FY2025 (Q4) vs FY2024 (Q4)